NCT03322215 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03322215
Title	HR+/HER2- Advanced Breast Cancer and Endocrine Resistance (PASIPHAE)
Acronym	PASIPHAE
Recruitment	Terminated
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	Theodoros Foukakis
Indications	Her2-receptor negative breast cancer
Therapies	Capecitabine Fulvestrant + Palbociclib
Age Groups:	senior \| adult
Covered Countries	SWE \| GBR

Filter rows:

Showing 1 to 9 of 9 entries

Facility	City	Zip	Country	Details
Beatson	Glasgow	G12 0XH	United Kingdom	Details
Karolinska University Hospital	Stockholm		Sweden	Details
NHS Ayshire and Arran	Kilmarnock	KA2 OBE	United Kingdom	Details
NHS Grampian	Aberdeen	AB15 6RE	United Kingdom	Details
S:t Görans Hospital	Stockholm	112 19	Sweden	Details
Sahlgrenska University Hospital	Göteborg	413 45	Sweden	Details
Skåne University Hospital	Malmö	205 02	Sweden	Details
Uppsala University Hospital	Uppsala	751 85	Sweden	Details
Western General Hospital	Edinburgh	EH1 3EG	United Kingdom	Details

Showing 1 to 9 of 9 entries

Filter rows:

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT03322215Clinical Trial Detail